Leicester General Hospital

Running trials

• Not yet recruiting

  SYNCHRONIZE®-HERA: A Study to Test Whether Survodutide Helps Women Who Are Living With Overweight or Obesity and Are Going Through or Have Finished Menopause, to Lose Weight

  NCT07850050· Phase 3· Boehringer Ingelheim· Source

• Not yet recruiting

  A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or Obesity

  NCT07861100· Phase 3· Novo Nordisk A/S· Source

• Not yet recruiting

  Evaluation of the Safety and Effectiveness of the Novel Medtronic Experimental Automated Insulin Delivery System (NMX8) in Adults Living With Type 1 Diabetes

  NCT07401901· Medtronic MiniMed, Inc.· Source

• Active, not recruiting

  A Study to Test Whether BI 3034701 Helps People to Lose Weight Who Live With Obesity or Overweight

  NCT07662122· Phase 2· Boehringer Ingelheim· Source

• Recruiting

  PS-002 for the Treatment of IgA Nephropathy in Adults

  NCT07182227· Phase 1/2· Purespring Therapeutics Limited· Source

• Recruiting

  A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes

  NCT07351045· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases

  NCT06570798· Phase 2· Amgen· Source

• Recruiting

  A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy

  NCT06963827· Phase 3· Takeda· Source

• Recruiting

  A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)

  NCT06935357· Phase 3· Biogen· Source

• Recruiting

  Sotagliflozin in Patients With Heart Failure Symptoms and Type 1 Diabetes

  NCT06435156· Phase 2· University of Dundee· Source

• Active, not recruiting

  A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT06588855· Phase 3· Hoffmann-La Roche· Source

• Active, not recruiting

  Phase 2b Open-Label Repeat Kidney Biopsy Study

  NCT06740526· Phase 2· Otsuka Pharmaceutical Development & Commercialization, Inc.· Source

• Active, not recruiting

  Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN)

  NCT06564142· Phase 3· Alpine Immune Sciences Inc, A Subsidiary of Vertex· Source

• Active, not recruiting

  A Study of Obexelimab in Patients With Relapsing Multiple Sclerosis (MoonStone)

  NCT06564311· Phase 2· Zenas BioPharma (USA), LLC· Source

• Active, not recruiting

  A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression

  NCT05797610· Phase 3· Hoffmann-La Roche· Source

• Active, not recruiting

  CGM Use in Adults With Type 2 Diabetes on Basal Insulin

  NCT05944432· Abbott Diabetes Care· Source

• Active, not recruiting

  A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE

  NCT05702034· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  Implementation of Metformin theraPy to Ease Decline of Kidney Function in Polycystic Kidney Disease (IMPEDE-PKD)

  NCT04939935· Phase 3· The University of Queensland· Source

• Active, not recruiting

  A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

  NCT05556512· Phase 3· Eli Lilly and Company· Source

• Active, not recruiting

  A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 Diabetes

  NCT05433584· Phase 4· Eli Lilly and Company· Source

• Active, not recruiting

  Atrasentan in Patients With IgA Nephropathy

  NCT04573478· Phase 3· Novartis Pharmaceuticals· Source

• Recruiting

  Chronotype of Patients With Diabetes and Effect on Glycaemic Control

  NCT02973412· University of Leicester· Source

• Recruiting

  Exactech Shoulder Post Market Clinical Follow-up Study

  NCT05603728· Exactech· Source

• Active, not recruiting

  Prostate Testing for Cancer and Treatment

  NCT02044172· University of Oxford· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• IgA nephropathy3 recruiting
• Obesity3 recruiting
• Type 1 diabetes3 recruiting
• Type 2 diabetes3 recruiting
• Rheumatoid arthritis2 recruiting
• Ankylosing spondylitis1 recruiting
• Heart failure1 recruiting
• Lupus (SLE)1 recruiting
• Osteoarthritis1 recruiting
• Polycystic kidney disease1 recruiting

Closed trials

• Completed

  A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)

  NCT06077864· Phase 3· Boehringer Ingelheim· Source

• Completed

  A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee

  NCT05931367· Phase 3· Eli Lilly and Company· Source

• Completed

  A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight

  NCT05929066· Phase 3· Eli Lilly and Company· Source

• Completed

  A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose Weight

  NCT05394519· Phase 3· Novo Nordisk A/S· Source

• Completed

  A Study of Mezagitamab in Adults With Primary Immunoglobulin A Nephropathy Receiving Stable Background Therapy

  NCT05174221· Phase 1· Takeda· Source

• Completed

  Efficacy and Safety in Imlifidase Desensitized Kidney Tx Patients, Including Two Non-Comparative Reference Cohorts

  NCT05369975· Phase 3· Hansa Biopharma AB· Source

• Completed

  A Study to Evaluate Tirzepatide (LY3298176) in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin or Basal Insulin or Both

  NCT05260021· Phase 3· Eli Lilly and Company· Source

• Completed

  ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation

  NCT05021835· Phase 3· Novo Nordisk A/S· Source

• Terminated

  IMCY-0098 Proof of ACtion in Type 1 Diabetes (IMPACT Study)

  NCT04524949· Phase 2· Imcyse SA· Source

• Completed

  A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes

  NCT04255433· Phase 3· Eli Lilly and Company· Source

• Completed

  TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations

  NCT04129502· Phase 3· Takeda· Source

• Completed

  Aldosterone bloCkade for Health Improvement EValuation in End-stage Renal Disease

  NCT03020303· Phase 3· Hamilton Health Sciences Corporation· Source

Conditions

Diseases this institution publishes on or runs trials for.

• IgA nephropathy8 works · 8 trials